{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T20:33:48Z","timestamp":1793306028604,"version":"4.5.0"},"reference-count":76,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,10]],"date-time":"2024-09-10T00:00:00Z","timestamp":1725926400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["euoncology.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Oncology"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.euo.2024.09.002","type":"journal-article","created":{"date-parts":[[2024,9,25]],"date-time":"2024-09-25T17:40:22Z","timestamp":1727286022000},"page":"494-509","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"title":["Neoadjuvant and Adjuvant Immune-based Approach for Renal Cell Carcinoma: Pros, Cons, and Future Directions"],"prefix":"10.1016","volume":"8","author":[{"given":"Laura","family":"Marandino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Campi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Amparore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zayd","family":"Tippu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Albiges","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umberto","family":"Capitanio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel H.","family":"Giles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silke","family":"Gillessen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Kutikov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Larkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Motzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phillip M.","family":"Pierorazio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Powles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morgan","family":"Roupret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grant D.","family":"Stewart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samra","family":"Turajlic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel","family":"Bex","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euo.2024.09.002_b0005","doi-asserted-by":"crossref","first-page":"e1264","DOI":"10.1200\/OP.20.00105","article-title":"Fear of cancer recurrence in patients with localized renal cell carcinoma","volume":"16","author":"Bergerot","year":"2020","journal-title":"JCO Oncol Pract"},{"key":"10.1016\/j.euo.2024.09.002_b0010","doi-asserted-by":"crossref","first-page":"190","DOI":"10.6004\/jnccn.2013.0027","article-title":"Distress management","volume":"11","author":"Holland","year":"2013","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.euo.2024.09.002_b0015","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1056\/NEJMoa1611406","article-title":"Adjuvant sunitinib in high-risk renal-cell carcinoma after nephrectomy","volume":"375","author":"Ravaud","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2024.09.002_b0020","doi-asserted-by":"crossref","first-page":"3916","DOI":"10.1200\/JCO.2017.73.5324","article-title":"Randomized phase III trial of adjuvant pazopanib versus placebo after nephrectomy in patients with localized or locally advanced renal cell carcinoma","volume":"35","author":"Motzer","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2024.09.002_b0025","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1016\/S0140-6736(16)00559-6","article-title":"Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial","volume":"387","author":"Haas","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.euo.2024.09.002_b0030","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1093\/annonc\/mdy454","article-title":"Axitinib versus placebo as an adjuvant treatment of renal cell carcinoma: results from the phase III, randomized ATLAS trial","volume":"29","author":"Gross-Goupil","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.euo.2024.09.002_b0035","doi-asserted-by":"crossref","first-page":"4064","DOI":"10.1200\/JCO.20.01800","article-title":"Adjuvant sorafenib for renal cell carcinoma at intermediate or high risk of relapse: results from the SORCE randomized phase III intergroup trial","volume":"38","author":"Eisen","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2024.09.002_b0040","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/S0140-6736(23)00913-3","article-title":"Adjuvant everolimus after surgery for renal cell carcinoma (EVEREST): a double-blind, placebo-controlled, randomised, phase 3 trial","volume":"402","author":"Ryan","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.euo.2024.09.002_b0045","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1056\/NEJMoa2106391","article-title":"Adjuvant pembrolizumab after nephrectomy in renal-cell carcinoma","volume":"385","author":"Choueiri","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2024.09.002_b0050","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1016\/S0140-6736(22)01658-0","article-title":"Adjuvant atezolizumab versus placebo for patients with renal cell carcinoma at increased risk of recurrence following resection (IMmotion010): a multicentre, randomised, double-blind, phase 3 trial","volume":"400","author":"Pal","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.euo.2024.09.002_b0055","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/S0140-6736(22)02574-0","article-title":"Adjuvant nivolumab plus ipilimumab versus placebo for localised renal cell carcinoma after nephrectomy (CheckMate 914): a double-blind, randomised, phase 3 trial","volume":"401","author":"Motzer","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.euo.2024.09.002_b0060","doi-asserted-by":"crossref","first-page":"S1432","DOI":"10.1016\/j.annonc.2022.08.072","article-title":"LBA67 Phase III randomized study comparing perioperative nivolumab (nivo) versus observation in patients (Pts) with renal cell carcinoma (RCC) undergoing nephrectomy (PROSPER, ECOG-ACRIN EA8143), a National Clinical Trials Network trial","volume":"33","author":"Allaf","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.euo.2024.09.002_b0065","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/S0140-6736(23)01128-5","article-title":"TNM-based risk eligibility for adjuvant trials in renal cell carcinoma","volume":"402","author":"Bedke","year":"2023","journal-title":"Lancet"},{"issue":"4_suppl","key":"10.1016\/j.euo.2024.09.002_b0070","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.4_suppl.LBA359","article-title":"Overall survival results from the phase 3 KEYNOTE-564 study of adjuvant pembrolizumab versus placebo for the treatment of clear cell renal cell carcinoma (ccRCC)","volume":"42","author":"Choueiri","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2024.09.002_b0075","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1056\/NEJMoa2312695","article-title":"Overall survival with adjuvant pembrolizumab in renal-cell carcinoma","volume":"390","author":"Choueiri","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2024.09.002_b0080","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/j.trecan.2023.07.011","article-title":"Genitourinary cancer neoadjuvant therapies: current and future approaches","volume":"9","author":"Nair","year":"2023","journal-title":"Trends Cancer"},{"key":"10.1016\/j.euo.2024.09.002_b0085","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1038\/s41591-018-0198-0","article-title":"Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma","volume":"24","author":"Blank","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.euo.2024.09.002_b0090","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.annonc.2023.01.004","article-title":"Survival update of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma in the OpACIN and OpACIN-neo trials","volume":"34","author":"Versluis","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.euo.2024.09.002_b0095","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1038\/s41591-020-0805-8","article-title":"Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers","volume":"26","author":"Chalabi","year":"2020","journal-title":"Nat Med"},{"key":"10.1016\/j.euo.2024.09.002_b0100","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1056\/NEJMoa2202170","article-title":"Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer","volume":"386","author":"Forde","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2024.09.002_b0105","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1056\/NEJMoa2211437","article-title":"Neoadjuvant-adjuvant or adjuvant-only pembrolizumab in advanced melanoma","volume":"388","author":"Patel","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2024.09.002_b0110","doi-asserted-by":"crossref","unstructured":"Blank CU, Lucas MW, Scolyer RA, et al. Neoadjuvant nivolumab and ipilimumab in resectable stage III melanoma. N Engl J Med, in press. https:\/\/doi.org\/10.1056\/NEJMoa2402604.","DOI":"10.1056\/NEJMoa2402604"},{"key":"10.1016\/j.euo.2024.09.002_b0115","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1056\/NEJMoa2400634","article-title":"Neoadjuvant immunotherapy in locally advanced mismatch repair-deficient colon cancer","volume":"390","author":"Chalabi","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2024.09.002_b0120","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1177\/1756287215612962","article-title":"The role of neoadjuvant therapy in the management of locally advanced renal cell carcinoma","volume":"8","author":"Borregales","year":"2016","journal-title":"Ther Adv Urol"},{"key":"10.1016\/j.euo.2024.09.002_b0125","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.eururo.2022.01.043","article-title":"Phase II study of neoadjuvant nivolumab in patients with locally advanced clear cell renal cell carcinoma undergoing nephrectomy","volume":"81","author":"Carlo","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2024.09.002_b0130","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.euo.2021.04.002","article-title":"Neoadjuvant nivolumab in patients with high-risk nonmetastatic renal cell carcinoma","volume":"5","author":"Gorin","year":"2022","journal-title":"Eur Urol Oncol"},{"issue":"15_suppl","key":"10.1016\/j.euo.2024.09.002_b0135","doi-asserted-by":"crossref","first-page":"5021","DOI":"10.1200\/JCO.2020.38.15_suppl.5021","article-title":"A phase Ib trial of neoadjuvant\/adjuvant durvalumab +\/- tremelimumab in locally advanced renal cell carcinoma (RCC)","volume":"38","author":"Ornstein","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2024.09.002_b0140","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1038\/s41467-023-38342-7","article-title":"Phase II trial of neoadjuvant sitravatinib plus nivolumab in patients undergoing nephrectomy for locally advanced clear cell renal cell carcinoma","volume":"14","author":"Karam","year":"2023","journal-title":"Nat Commun"},{"issue":"6_suppl","key":"10.1016\/j.euo.2024.09.002_b0145","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1200\/JCO.2022.40.6_suppl.289","article-title":"Efficacy, safety, and biomarker analysis of neoadjuvant avelumab\/axitinib in patients (pts) with localized renal cell carcinoma (RCC) who are at high risk of relapse after nephrectomy (NeoAvAx)","volume":"40","author":"Bex","year":"2022","journal-title":"J Clin Oncol"},{"issue":"4_suppl","key":"10.1016\/j.euo.2024.09.002_b0150","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.4_suppl.LBA358","article-title":"Adjuvant nivolumab monotherapy vs placebo for localized renal cell carcinoma at high risk of relapse after nephrectomy: results from Part B of the randomized, phase 3 CheckMate 914 trial","volume":"42","author":"Motzer","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2024.09.002_b0155","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.euo.2023.10.023","article-title":"Could a risk-adapted approach support shared decision-making regarding eligibility for adjuvant pembrolizumab for patients with clear cell renal cell carcinoma at high risk of recurrence? A multicentre cohort study","volume":"7","author":"Campi","year":"2024","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euo.2024.09.002_b0160","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1007\/s00345-022-04153-6","article-title":"How to optimize the use of adjuvant pembrolizumab in renal cell carcinoma: which patients benefit the most?","volume":"40","author":"Fallara","year":"2022","journal-title":"World J Urol"},{"key":"10.1016\/j.euo.2024.09.002_b0165","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1016\/j.urolonc.2024.01.045","article-title":"Safety of partial and radical nephrectomy for complex locally advanced renal cell carcinoma after neo-adjuvant immune checkpoint inhibition (durvalumab +\/- tremelimumab)","volume":"42","author":"Scovell","year":"2024","journal-title":"Urol Oncol"},{"key":"10.1016\/j.euo.2024.09.002_b0170","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1158\/2159-8290.CD-16-0577","article-title":"Improved efficacy of neoadjuvant compared to adjuvant immunotherapy to eradicate metastatic disease","volume":"6","author":"Liu","year":"2016","journal-title":"Cancer Discov"},{"key":"10.1016\/j.euo.2024.09.002_b0175","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/s41591-018-0337-7","article-title":"Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma","volume":"25","author":"Cloughesy","year":"2019","journal-title":"Nat Med"},{"key":"10.1016\/j.euo.2024.09.002_b0180","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1158\/1538-7445.AM2018-1719","article-title":"Abstract 1719: Superior efficacy of neoadjuvant compared to adjuvant immune checkpoint blockade in non-small cell lung cancer","volume":"78","author":"Cascone","year":"2018","journal-title":"Cancer Res"},{"key":"10.1016\/j.euo.2024.09.002_b0185","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1158\/1078-0432.CCR-19-2209","article-title":"Neoadjuvant PD-1 immune checkpoint blockade reverses functional immunodominance among tumor antigen-specific T cells","volume":"26","author":"Friedman","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.euo.2024.09.002_b0190","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1158\/2159-8290.CD-18-0367","article-title":"Fundamental mechanisms of immune checkpoint blockade therapy","volume":"8","author":"Wei","year":"2018","journal-title":"Cancer Discov"},{"key":"10.1016\/j.euo.2024.09.002_b0195","first-page":"1","article-title":"Neoadjuvant immunotherapy: leveraging the immune system to treat early-stage disease","volume":"42","author":"Mittendorf","year":"2022","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"10.1016\/j.euo.2024.09.002_b0200","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.ccell.2020.08.005","article-title":"Conserved interferon-\u03b3 signaling drives clinical response to immune checkpoint blockade therapy in melanoma","volume":"38","author":"Grasso","year":"2020","journal-title":"Cancer Cell"},{"key":"10.1016\/j.euo.2024.09.002_b0205","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.eururo.2021.05.020","article-title":"Primary renal tumour response in patients treated with nivolumab for metastatic renal cell carcinoma: results from the GETUG-AFU 26 NIVOREN trial","volume":"80","author":"Courcier","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2024.09.002_b0210","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.cell.2018.03.043","article-title":"Deterministic evolutionary trajectories influence primary tumor growth: TRACERx renal","volume":"173","author":"Turajlic","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.euo.2024.09.002_b0215","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1113205","article-title":"Intratumor heterogeneity and branched evolution revealed by multiregion sequencing","volume":"366","author":"Gerlinger","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2024.09.002_b0220","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/j.hoc.2023.05.020","article-title":"Adjuvant and neoadjuvant therapy in renal cell carcinoma","volume":"37","author":"Kuusk","year":"2023","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.euo.2024.09.002_b0225","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.ucl.2020.04.010","article-title":"Neoadjuvant therapy for locally advanced renal cell carcinoma","volume":"47","author":"Westerman","year":"2020","journal-title":"Urol Clin North Am"},{"key":"10.1016\/j.euo.2024.09.002_b0230","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1038\/s41416-022-01883-7","article-title":"A phase II study of neoadjuvant axitinib for reducing the extent of venous tumour thrombus in clear cell renal cell cancer with venous invasion (NAXIVA)","volume":"127","author":"Stewart","year":"2022","journal-title":"Br J Cancer"},{"key":"10.1016\/j.euo.2024.09.002_b0235","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.euros.2021.11.003","article-title":"Primary renal tumour response in patients treated with nivolumab and ipilimumab for metastatic renal cell carcinoma: real-world data assessment","volume":"35","author":"Meerveld-Eggink","year":"2022","journal-title":"Eur Urol Open Sci"},{"key":"10.1016\/j.euo.2024.09.002_b0240","doi-asserted-by":"crossref","first-page":"v359","DOI":"10.1093\/annonc\/mdz249.007","volume":"30","author":"Albiges","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.euo.2024.09.002_b0245","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.eururo.2021.10.001","article-title":"First-line nivolumab plus ipilimumab versus sunitinib in patients without nephrectomy and with an evaluable primary renal tumor in the CheckMate 214 trial","volume":"81","author":"Albiges","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2024.09.002_b0250","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.eururo.2019.11.015","article-title":"Intraoperative adverse incident classification (EAUiaiC) by the European Association of Urology ad hoc Complications Guidelines Panel","volume":"77","author":"Biyani","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2024.09.002_b0255","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1097\/SLA.0b013e3181b13ca2","article-title":"The Clavien-Dindo classification of surgical complications: five-year experience","volume":"250","author":"Clavien","year":"2009","journal-title":"Ann Surg"},{"key":"10.1016\/j.euo.2024.09.002_b0260","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1097\/SLA.0000000000002132","article-title":"The Comprehensive Complication Index (CCI\u00ae): added value and clinical perspectives 3 years \u201cdown the line\u201d","volume":"265","author":"Clavien","year":"2017","journal-title":"Ann Surg"},{"key":"10.1016\/j.euo.2024.09.002_b0265","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.eururo.2022.02.013","article-title":"Neoadjuvant treatment in renal cell carcinoma: transforming challenges into opportunities","volume":"81","author":"Marandino","year":"2022","journal-title":"Eur Urol"},{"issue":"6_suppl","key":"10.1016\/j.euo.2024.09.002_b0270","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1200\/JCO.2018.36.6_suppl.644","article-title":"Patients perspectives on adjuvant therapy in renal cell carcinoma","volume":"36","author":"Battle","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2024.09.002_b0275","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.euo.2024.09.002_b0280","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.27145","article-title":"Extended follow-up of chronic immune-related adverse events following adjuvant anti-PD-1 therapy for high-risk resected melanoma","volume":"6","author":"Goodman","year":"2023","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.euo.2024.09.002_b0285","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.ejca.2021.03.010","article-title":"Late-onset and long-lasting immune-related adverse events from immune checkpoint-inhibitors: an overlooked aspect in immunotherapy","volume":"149","author":"Ghisoni","year":"2021","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.euo.2024.09.002_b0290","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1186\/s40425-019-0645-6","article-title":"Delayed immune-related events (DIRE) after discontinuation of immunotherapy: diagnostic hazard of autoimmunity at a distance","volume":"7","author":"Couey","year":"2019","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.euo.2024.09.002_b0295","doi-asserted-by":"crossref","first-page":"e000371","DOI":"10.1136\/jitc-2019-000371","article-title":"Conditional immune toxicity rate in patients with metastatic renal and urothelial cancer treated with immune checkpoint inhibitors","volume":"8","author":"Nuzzo","year":"2020","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.euo.2024.09.002_b0300","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/S1470-2045(22)00487-9","article-title":"Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"23","author":"Powles","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euo.2024.09.002_b0305","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1093\/oncolo\/oyad231","article-title":"Patient-reported outcomes in KEYNOTE-564: adjuvant pembrolizumab versus placebo for renal cell carcinoma","volume":"29","author":"Choueiri","year":"2024","journal-title":"Oncologist"},{"key":"10.1016\/j.euo.2024.09.002_b0310","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1002\/cncr.34180","article-title":"Conditional survival and long-term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma","volume":"128","author":"Motzer","year":"2022","journal-title":"Cancer"},{"key":"10.1016\/j.euo.2024.09.002_b0315","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1016\/S1470-2045(19)30151-2","article-title":"Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial","volume":"20","author":"Rozeman","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euo.2024.09.002_b0320","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1038\/s41591-022-01851-x","article-title":"Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial","volume":"28","author":"Reijers","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.euo.2024.09.002_b0325","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1056\/NEJMoa2034442","article-title":"Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinoma","volume":"384","author":"Bajorin","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2024.09.002_b0330","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1038\/s41591-023-02660-6","article-title":"Association between pathologic response and survival after neoadjuvant therapy in lung cancer","volume":"30","author":"Deutsch","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.euo.2024.09.002_b0335","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1093\/annonc\/mdy226","article-title":"Pathological assessment of resection specimens after neoadjuvant therapy for metastatic melanoma","volume":"29","author":"Tetzlaff","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.euo.2024.09.002_b0340","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1093\/annonc\/mdv161","article-title":"Recommendations for standardized pathological characterization of residual disease for neoadjuvant clinical trials of breast cancer by the BIG-NABCG collaboration","volume":"26","author":"Bossuyt","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.euo.2024.09.002_b0345","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.jtho.2020.01.005","article-title":"IASLC multidisciplinary recommendations for pathologic assessment of lung cancer resection specimens after neoadjuvant therapy","volume":"15","author":"Travis","year":"2020","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.euo.2024.09.002_b0350","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41698-024-00532-x","article-title":"UroPredict: Machine learning model on real-world data for prediction of kidney cancer recurrence (UroCCR-120)","volume":"8","author":"Margue","year":"2024","journal-title":"NPJ Precis Oncol"},{"key":"10.1016\/j.euo.2024.09.002_b0355","doi-asserted-by":"crossref","first-page":"3397","DOI":"10.1158\/1078-0432.CCR-21-0025","article-title":"Plasma KIM-1 is associated with recurrence risk after nephrectomy for localized renal cell carcinoma: a trial of the ECOG-ACRIN Research Group (E2805)","volume":"27","author":"Xu","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"16_suppl","key":"10.1016\/j.euo.2024.09.002_b0360","doi-asserted-by":"crossref","first-page":"4506","DOI":"10.1200\/JCO.2024.42.16_suppl.4506","volume":"42","author":"Albiges","year":"2024","journal-title":"J Clin Oncol"},{"issue":"6_Suppl","key":"10.1016\/j.euo.2024.09.002_b0365","doi-asserted-by":"crossref","first-page":"5151","DOI":"10.1158\/1538-7445.AM2024-5151","article-title":"Abstract 5151: High serum kidney injury marker-1 and high baseline tumor PD-L1 protein expression levels are independently associated with treatment effect in adjuvant nivolumab plus ipilimumab vs placebo in localized clear cell renal cell carcinoma","volume":"84","author":"Vemula","year":"2024","journal-title":"Cancer Res"},{"key":"10.1016\/j.euo.2024.09.002_b0370","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1097\/PAP.0000000000000162","volume":"24","author":"Hendry","year":"2017","journal-title":"Adv Anat Pathol"},{"key":"10.1016\/j.euo.2024.09.002_b0375","doi-asserted-by":"crossref","first-page":"5365","DOI":"10.1158\/1078-0432.CCR-21-0144","article-title":"Immune phenotype and response to neoadjuvant therapy in triple-negative breast cancer","volume":"27","author":"Yam","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.euo.2024.09.002_b0380","article-title":"Combinatorial biomarker for predicting outcomes to anti-PD-1 therapy in patients with metastatic clear cell renal cell carcinoma","volume":"4","author":"Deutsch","year":"2023","journal-title":"Cell Rep Med"}],"container-title":["European Urology Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931124002116?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931124002116?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T05:51:36Z","timestamp":1744869096000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2588931124002116"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":76,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["S2588931124002116"],"URL":"https:\/\/doi.org\/10.1016\/j.euo.2024.09.002","relation":{},"ISSN":["2588-9311"],"issn-type":[{"value":"2588-9311","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neoadjuvant and Adjuvant Immune-based Approach for Renal Cell Carcinoma: Pros, Cons, and Future Directions","name":"articletitle","label":"Article Title"},{"value":"European Urology Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euo.2024.09.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier B.V. on behalf of European Association of Urology.","name":"copyright","label":"Copyright"}]}}